诺华-话题@MedSci

#诺华#

235篇内容 | 5259人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1282773, encodeId=9dd71282e7354, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, objectType=article, longId=180601, objectId=697618060195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=697618060195, replyNumber=0, likeNumber=136, createdTime=2019-10-08, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=697618060195, moduleTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=697618060195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282772, encodeId=3c911282e7288, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华与微软达成协议，使用人工智能加速药物开发, objectType=article, longId=180388, objectId=8d4d180388ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d4d180388ee, replyNumber=0, likeNumber=64, createdTime=2019-10-04, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d4d180388ee, moduleTitle=诺华与微软达成协议，使用人工智能加速药物开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d4d180388ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282771, encodeId=21661282e71dd, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=每年5000英镑的治疗费用，诺华Erenumab偏头痛药物未达到NICE推荐标准, objectType=article, longId=180137, objectId=a97d18013e74, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a97d18013e74, replyNumber=0, likeNumber=73, createdTime=2019-09-29, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a97d18013e74, moduleTitle=每年5000英镑的治疗费用，诺华Erenumab偏头痛药物未达到NICE推荐标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a97d18013e74)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282770, encodeId=9e731282e7063, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=NICE推荐将诺华的Luxturna基因疗法用于治疗双等位RPE65突变引起的视力丧失, objectType=article, longId=178918, objectId=0b251e891861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b251e891861, replyNumber=0, likeNumber=70, createdTime=2019-09-07, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b251e891861, moduleTitle=NICE推荐将诺华的Luxturna基因疗法用于治疗双等位RPE65突变引起的视力丧失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b251e891861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282769, encodeId=4c7d1282e69fb, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=2019ESC：诺华公司的Entresto将心衰住院率和心血管死亡率降低了13％, objectType=article, longId=178635, objectId=48731e863545, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48731e863545, replyNumber=0, likeNumber=66, createdTime=2019-09-04, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48731e863545, moduleTitle=2019ESC：诺华公司的Entresto将心衰住院率和心血管死亡率降低了13％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48731e863545)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282768, encodeId=df011282e6802, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, objectType=article, longId=178542, objectId=bc501e854207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc501e854207, replyNumber=0, likeNumber=162, createdTime=2019-09-03, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc501e854207, moduleTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc501e854207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282767, encodeId=df6c1282e671f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华天价药存在“人为操纵数据”问题，刚获FDA批准2个月, objectType=article, longId=177220, objectId=dcf01e7220df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcf01e7220df, replyNumber=0, likeNumber=79, createdTime=2019-08-09, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcf01e7220df, moduleTitle=诺华天价药存在“人为操纵数据”问题，刚获FDA批准2个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcf01e7220df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282766, encodeId=328e1282e661a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华一剂210万美元基因疗法有瑕疵，FDA：隐瞒数据问题, objectType=article, longId=177180, objectId=ab431e718012, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab431e718012, replyNumber=0, likeNumber=78, createdTime=2019-08-09, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab431e718012, moduleTitle=诺华一剂210万美元基因疗法有瑕疵，FDA：隐瞒数据问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab431e718012)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282765, encodeId=bad41282e652f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代, objectType=article, longId=177001, objectId=9f851e70016d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f851e70016d, replyNumber=0, likeNumber=57, createdTime=2019-08-07, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f851e70016d, moduleTitle=**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f851e70016d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282764, encodeId=2dc61282e64b5, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=全新临床失败、加速评估被撤、用药被限制诺华近期有点背！, objectType=article, longId=176553, objectId=96671e655374, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96671e655374, replyNumber=0, likeNumber=76, createdTime=2019-08-02, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96671e655374, moduleTitle=全新临床失败、加速评估被撤、用药被限制诺华近期有点背！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96671e655374)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282763, encodeId=0ba01282e636a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌, objectType=article, longId=175681, objectId=3cfe1e5681e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cfe1e5681e2, replyNumber=0, likeNumber=90, createdTime=2019-07-19, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cfe1e5681e2, moduleTitle=诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cfe1e5681e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282762, encodeId=30651282e629f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华抗镰状细胞病血管闭塞性危象单抗crizanlizumab，获得FDA快速审查, objectType=article, longId=175670, objectId=12af1e5670b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12af1e5670b6, replyNumber=0, likeNumber=81, createdTime=2019-07-19, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12af1e5670b6, moduleTitle=诺华抗镰状细胞病血管闭塞性危象单抗crizanlizumab，获得FDA快速审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12af1e5670b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282761, encodeId=b2fe1282e61c4, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华以3.9亿美元将3种内分泌药物卖给Recordati公司, objectType=article, longId=175612, objectId=f1bb1e561250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bb1e561250, replyNumber=0, likeNumber=66, createdTime=2019-07-18, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bb1e561250, moduleTitle=诺华以3.9亿美元将3种内分泌药物卖给Recordati公司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bb1e561250)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282760, encodeId=d04c1282e6091, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=又一个阿尔茨海默氏症的候选药宣布失败：安进、诺华放弃BACE抑制剂试验, objectType=article, longId=175370, objectId=81a41e537040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81a41e537040, replyNumber=0, likeNumber=70, createdTime=2019-07-14, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81a41e537040, moduleTitle=又一个阿尔茨海默氏症的候选药宣布失败：安进、诺华放弃BACE抑制剂试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81a41e537040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282759, encodeId=91bf1282e590d, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, objectType=article, longId=174669, objectId=3b101e46693f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b101e46693f, replyNumber=0, likeNumber=66, createdTime=2019-07-03, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b101e46693f, moduleTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b101e46693f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282758, encodeId=04c41282e581c, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状, objectType=article, longId=173291, objectId=9eb91e32918d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9eb91e32918d, replyNumber=0, likeNumber=68, createdTime=2019-06-28, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9eb91e32918d, moduleTitle=诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9eb91e32918d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282757, encodeId=f98c1282e57c8, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=2019 ATC：诺华的抗CD40单抗iscalimab可提高肾移植的耐受性并改善长期预后, objectType=article, longId=168059, objectId=552b1680597c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=552b1680597c, replyNumber=0, likeNumber=75, createdTime=2019-06-12, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=552b1680597c, moduleTitle=2019 ATC：诺华的抗CD40单抗iscalimab可提高肾移植的耐受性并改善长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=552b1680597c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282756, encodeId=13341282e56aa, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=2019 ASCO：诺华和默克治疗MET突变非小细胞肺癌的候选药，在2期临床均显示出治疗活性, objectType=article, longId=167679, objectId=019216e679c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=019216e679c8, replyNumber=0, likeNumber=66, createdTime=2019-06-06, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=019216e679c8, moduleTitle=2019 ASCO：诺华和默克治疗MET突变非小细胞肺癌的候选药，在2期临床均显示出治疗活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=019216e679c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282755, encodeId=2d7f1282e55fa, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点, objectType=article, longId=167612, objectId=933416e61276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=933416e61276, replyNumber=0, likeNumber=72, createdTime=2019-06-05, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=933416e61276, moduleTitle=2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=933416e61276)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282754, encodeId=f42f1282e54b7, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华IgE单抗Xolair治疗慢性鼻窦炎的两项III期研究达到主要临床终点, objectType=article, longId=167609, objectId=9e4316e6096f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e4316e6096f, replyNumber=0, likeNumber=64, createdTime=2019-06-05, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e4316e6096f, moduleTitle=诺华IgE单抗Xolair治疗慢性鼻窦炎的两项III期研究达到主要临床终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e4316e6096f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

诺华

2020-05-29发表于威斯康星

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功

2019-10-08

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华与微软达成协议，使用人工智能加速药物开发

2019-10-04

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

每年5000英镑的治疗费用，诺华Erenumab偏头痛药物未达到NICE推荐标准

2019-09-29

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

NICE推荐将诺华的Luxturna基因疗法用于治疗双等位RPE65突变引起的视力丧失

2019-09-07

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

2019ESC：诺华公司的Entresto将心衰住院率和心血管死亡率降低了13％

2019-09-04

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功

2019-09-03

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华天价药存在“人为操纵数据”问题，刚获FDA批准2个月

2019-08-09

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华一剂210万美元基因疗法有瑕疵，FDA：隐瞒数据问题

2019-08-09

柳叶一刀 (审核中...)

前往app查看评论内容

#诺华#

**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代

2019-08-07

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

全新临床失败、加速评估被撤、用药被限制诺华近期有点背！

2019-08-02

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌

2019-07-19

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华抗镰状细胞病血管闭塞性危象单抗crizanlizumab，获得FDA快速审查

2019-07-19

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华以3.9亿美元将3种内分泌药物卖给Recordati公司

2019-07-18

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

又一个阿尔茨海默氏症的候选药宣布失败：安进、诺华放弃BACE抑制剂试验

2019-07-14

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效

2019-07-03

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状

2019-06-28

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

2019 ATC：诺华的抗CD40单抗iscalimab可提高肾移植的耐受性并改善长期预后

2019-06-12

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

2019 ASCO：诺华和默克治疗MET突变非小细胞肺癌的候选药，在2期临床均显示出治疗活性

2019-06-06

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点

2019-06-05

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华IgE单抗Xolair治疗慢性鼻窦炎的两项III期研究达到主要临床终点

2019-06-05

科室
- - 订阅+
  - 更多科室
工具
服务